Clinical Trials Logo

Clinical Trial Details — Status: Suspended

Administrative data

NCT number NCT03432741
Other study ID # MC1689
Secondary ID NCI-2018-00149MC
Status Suspended
Phase Phase 1
First received
Last updated
Start date March 27, 2018
Est. completion date May 1, 2026

Study information

Verified date September 2023
Source Mayo Clinic
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This pilot phase I trial studies the side effects of direct tumor microinjection and fludeoxyglucose F-18 positron emission tomography (FDG-PET) in testing drug sensitivity in patients with non-Hodgkin lymphoma, Hodgkin lymphoma, or stage IV breast cancer that has returned after a period of improvement or does not respond to treatment. Injecting tiny amounts of anti-cancer drugs directly into tumors on the skin or in lymph nodes and diagnostic procedures, such as FDG-PET, may help to show which drugs work better in treating patients with non-Hodgkin lymphoma, Hodgkin lymphoma, or breast cancer.


Description:

PRIMARY OBJECTIVE: I. To assess the safety of in vivo in host drug sensitivity testing in patients with breast cancer and patients with lymphoma (nodal, extranodal masses, or cutaneous lesions). SECONDARY OBJECTIVES: I. To assess the feasibility of in vivo in host drug sensitivity testing in this patient population. II. To identify targeted therapies with potential activity in relapsed lymphoma and metastatic breast cancer. III. To evaluate the adverse event profile within each patient population. CORRELATIVE OBJECTIVES: I. To assess for apoptosis in response to intratumoral injection using known biomarkers (e.g., by morphology, Ki-67, caspace-3 assay as a marker of early apoptosis). II. To evaluate intratumoral biomarkers, intratumoral cell populations, and distribution, identify potential biomarkers that correlate with response to therapy based on individual therapies. OUTLINE: Patients undergo FDG-PET and receive saline intralesionally on day 1. Patients also receive up to five additional injections of gemcitabine hydrochloride, romidepsin, belinostat, carfilzomib, copanlisib hydrochloride, nivolumab, trastuzumab, daratumumab, obinutuzumab, pembrolizumab, or rituximab intralesionally per investigator on day 1. Beginning 5 days later, patients with nodal/extranodal mass undergo restaging FDG-PET and biopsy (if clinically feasible). Within 3-7 days, patients with cutaneous disease undergo restaging photography and biopsy. After completion of study treatment, patients are followed up at 3 months.


Recruitment information / eligibility

Status Suspended
Enrollment 39
Est. completion date May 1, 2026
Est. primary completion date April 1, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age >= 18 years - Histologically proven of relapsed or refractory - Non-Hodgkin lymphoma (NHL) or Hodgkin lymphoma (HL) nodal or extranodal mass OR - Cutaneous T-cell lymphoma (CTCL) including mycosis fungoides (MF), as well as transformed MF OR - Breast adenocarcinoma with nodal or cutaneous metastases (stage 4) - NOTE: Patients must be refractory to or intolerant of existing therapy(ies) known to provide clinical benefit for their condition - NOTE: The patient must not be a candidate for any curative therapy or any known life-prolonging therapy - Cohort I: For nodal/extranodal mass, presence of lesions that are amenable for injections as determined by interventional radiology - NOTE: Nodal or extranodal mass must be palpable and easily accessible; masses such as mediastinum, retroperitoneum, within solid organs, spinal sites, central nervous system (CNS) sites, etc., are NOT allowed - Measurable disease: - For nodal or extranodal disease (lymphoma or breast): must have at least 2 lesions that are >= 20 mm (2.0 cm) in the longest diameter by physical exam and/or on cross-sectional imaging and measurable in two perpendicular dimensions per computed tomography PET-computed tomography (CT); For Cohort I, the lesions must be amenable to intralesional injections as determined by interventional radiology (including tumors that can be safely accessed using imaging guidance and treated with minimal risk to adjacent structures) - For cutaneous lesions (lymphoma or breast): at least two visible, non-infected skin lesions that are greater than 1 cm and are amenable to intralesional injection as determined by investigator - Candidate for further therapy and able to wait 7 days prior to start of next systemic therapy - Absolute neutrophil count (ANC) >= 1000/mm^3 (obtained =< 14 days prior to registration) - Platelet count >= 50,000/mm^3 (obtained =< 14 days prior to registration) - International normalized ratio (INR)/prothrombin time (PT) =< 1.5 (obtained =< 14 days prior to registration) - Negative serum or urine pregnancy test done =< 7 days prior to registration, for persons of childbearing potential only - Provide written informed consent - Willing to return to enrolling institution for follow-up - Willing to provide tissue samples for correlative research purposes Exclusion Criteria: - Any of the following: - Pregnant persons - Nursing persons - Persons of childbearing potential who are unwilling to employ adequate contraception - Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens - Systemic corticosteroids between pre-PET and post-PET evaluation and biopsy - Prohibited treatments and or therapies - Autologous stem cell transplant (ASCT) =< 12 weeks prior to registration - Prior chemotherapy =< 2 weeks prior to registration - Prior treatment with nitrosureas =< 4 weeks prior to registration - Therapeutic anticancer antibodies =< 2 weeks prior to registration - Radio- or toxin immunoconjugates =< 4 weeks prior to registration - Radiation therapy to the injected area =< 2 weeks prior to registration - Major surgery =< 2 weeks prior to registration - Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm - Requires anticoagulation that cannot be discontinued prior to biopsy - Note: Exception if able to hold antiplatelet agents 7 days prior to the injections and biopsy - NOTE: Low molecular weight heparin (LMWH) will be allowed for bridging if on warfarin - NOTE: Heparin for line patency without detectable lab abnormalities for coagulation will be allowed

Study Design


Related Conditions & MeSH terms

  • Breast Adenocarcinoma
  • Breast Neoplasms
  • Carcinoma
  • Hodgkin Disease
  • Lymphoma
  • Lymphoma, B-Cell, Marginal Zone
  • Lymphoma, Non-Hodgkin
  • Lymphoma, T-Cell
  • Lymphoma, T-Cell, Cutaneous
  • Metastatic Breast Carcinoma
  • Mycoses
  • Mycosis Fungoides
  • Recurrence
  • Recurrent Breast Carcinoma
  • Recurrent Hodgkin Lymphoma
  • Recurrent Mycosis Fungoides
  • Recurrent Non-Hodgkin Lymphoma
  • Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
  • Refractory Breast Carcinoma
  • Refractory Hodgkin Lymphoma
  • Refractory Mycosis Fungoides
  • Refractory Nodal Marginal Zone Lymphoma
  • Refractory Non-Hodgkin Lymphoma
  • Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
  • Stage IV Breast Cancer AJCC v6 and v7

Intervention

Drug:
Belinostat
Given intralesionally
Carfilzomib
Given intralesionally
Copanlisib Hydrochloride
Given intralesionally
Biological:
Daratumumab
Given intralesionally
Drug:
Fludeoxyglucose F-18
Undergo FDG-PET
Gemcitabine Hydrochloride
Given intralesionally
Other:
Laboratory Biomarker Analysis
Correlative studies
Biological:
Nivolumab
Given intralesionally
Obinutuzumab
Given intralesionally
Pembrolizumab
Given intralesionally
Procedure:
Positron Emission Tomography
Undergo FDG-PET
Biological:
Rituximab
Given intralesionally
Drug:
Romidepsin
Given intralesionally
Other:
Saline
Given intralesionally
Biological:
Trastuzumab
Given intralesionally

Locations

Country Name City State
United States Mayo Clinic in Rochester Rochester Minnesota

Sponsors (1)

Lead Sponsor Collaborator
Mayo Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Apoptosis in response to intratumoral injection Will assess using morphology (evidence of necrosis), measurement by immunohistochemistry of Ki67 (a marker of cell proliferation) and cleaved Caspace-3. Up to 3 months
Primary Incidence of drug sensitivity as measured by injection site skin reaction Skin reactions will be assessed using the Cancer Therapy Evaluation Program (CTEP) active version of the Common Terminology Criteria for Adverse Events (CTCAE) and will consist of any grade 3 or higher treatment-related pain, skin or subcutaneous tissue disorders. Incidence rates of skin reactions will be estimated by the number of patients with reactions divided by the total number of evaluable patients per disease type. Exact binomial 95% confidence intervals for the true incidence rate will be calculated. Up to 3 months
Secondary Feasibility For Cohort I (Arms A & B) and Cohort II (Arm D): The study will be determined to be feasible if at least 70% of the enrolled patients complete the injection and response evaluation. The feasibility rate will be estimated by the number of patients completed divided by the total number of evaluable patients. Exact binomial 95% confidence intervals for the true feasibility rate will be calculated. For Cohort II (Arm C): The feasibility rate will be evaluated for the device regarding whether the device will be able to target the affected lymph nodes in at least 50% of the time. The feasibility rate will be estimated by the number of patients completed divided by the total number of evaluable patients. Exact binomial 95% confidence intervals for the true feasibility rate will be calculated. Up to 3 months
Secondary Nodal disease response rate Defined as a decrease in standardized uptake value (SUV) uptake by 25% at site of injection. Will be estimated by the number of injection sites with responses divided by the total number of injected sites. Exact binomial 95% confidence intervals for the true overall response rate will be calculated. Up to 5 days post injection
Secondary Cutaneous response rate based upon the modified Severity Weighted Assessment Tool score Will be estimated by the number of injection sites with responses divided by the total number of injected sites. Exact binomial 95% confidence intervals for the true overall response rate will be calculated. Up to 7 days post injection
Secondary Incidence of adverse events Will be evaluated using the CTEP active version of the CTCAE. The maximum grade for each type of adverse event will be recorded for each patient, and frequency tables will be reviewed to determine patterns. Up to 3 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04052555 - Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer Phase 1
Recruiting NCT04521764 - A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer Phase 1
Completed NCT00100750 - Tipifarnib and Gemcitabine Hydrochloride in Treating Women With Metastatic Breast Cancer Phase 1/Phase 2
Suspended NCT03737695 - Clinical Information and Biospecimen Collection From Patients With Recurrent or Stage IV Breast Cancer
Active, not recruiting NCT02595905 - Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases Phase 2
Terminated NCT02149173 - F-18 FES PET/CT in Measuring Hormone Expression in Patients With Primary, Recurrent, or Metastatic Breast Cancer Undergoing Endocrine-Targeted Therapy N/A
Completed NCT00390455 - Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive Phase 3
Recruiting NCT03213041 - Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer Phase 2
Not yet recruiting NCT04529044 - 177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer Phase 2
Completed NCT00699491 - Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer Phase 1/Phase 2
Completed NCT03364348 - 4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer Phase 1
Terminated NCT01149356 - RO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast Cancer Phase 1
Completed NCT01964924 - Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer Phase 2
Completed NCT00785291 - Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer Phase 3
Terminated NCT02370264 - Questionnaires in Identifying Upper Extremity Function and Quality of Life After Treatment in Patients With Breast Cancer N/A
Terminated NCT00998738 - Calcium and Magnesium in Preventing Peripheral Neuropathy Caused by Ixabepilone in Patients With Breast Cancer Phase 3
Terminated NCT01071564 - RO4929097 and Vismodegib in Treating Patients With Breast Cancer That is Metastatic or Cannot Be Removed By Surgery Phase 1
Active, not recruiting NCT00520975 - First-Line Chemotherapy and Trastuzumab With or Without Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU Phase 3
Completed NCT01251874 - Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer Phase 1
Active, not recruiting NCT03281902 - Genetic Analysis in Blood and Tumor Samples From Patients With Advanced or Metastatic Estrogen Receptor Positive and HER2 Negative Breast Cancer Receiving Palbociclib and Endocrine Therapy

External Links